Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Mar;119(3):555-566.
doi: 10.1016/j.athoracsur.2024.11.025. Epub 2024 Dec 16.

Five- Year Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial

Vinod H Thourani  1 , Martin B Leon  2 , Raj Makkar  3 , Guido Ascione  4 , Wilson Y Szeto  5 , Mahesh V Madhavan  2 , Susheel K Kodali  6 , Rebecca T Hahn  2 , Philippe Pibarot  7 , S Chris Malaisrie  8 , Samir R Kapadia  9 , Mark J Russo  10 , Howard C Herrmann  11 , Vasilis Babaliaros  12 , Robert Guyton  12 , Philippe Genereux  13 , David J Cohen  14 , Brandon Park  15 , Sarah Clarke  15 , Marissa Gunnarsson  15 , Molly Szerlip  16 , Julien Ternacle  17 , Jonathon Leipsic  18 , Philipp Blanke  18 , John G Webb  18 , Craig R Smith  19 , Michael J Mack  16
Affiliations
Randomized Controlled Trial

Five- Year Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial

Vinod H Thourani et al. Ann Thorac Surg. 2025 Mar.

Abstract

Background: Surgery remains an important treatment for low-risk patients with severe symptomatic aortic stenosis (AS). This study evaluated 5-year outcomes in low-risk patients undergoing isolated surgical aortic valve replacement (SAVR) or SAVR with concomitant procedures within the randomized Placement of Aortic Transcatheter Valves (PARTNER) 3 trial.

Methods: In the PARTNER 3 trial, 454 patients underwent surgery for severe, symptomatic, trileaflet AS and were followed up for 5 years. Patients were stratified into those undergoing isolated SAVR (n = 334; 73.6%) vs concomitant SAVR (n = 120; 26.4%). Short- and long-term morbidity was adjudicated by a Clinical Events Committee. Hemodynamic valve performance was evaluated by an echocardiographic core laboratory. Patient-reported health status was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ).

Results: The mean age of participants was 73.6 ± 6.1 years; 71.1% of these patients were male. The median SAVR implant size was 23 mm overall. Five-year all-cause mortality (with vital status sweep) was 9.0% for all patients (8.5% isolated SAVR; 10.2% concomitant SAVR; P = .58), comparable to a recent analysis of low-risk isolated SAVR-treated patients in the STS database (overall mortality, 7.1%). The average 5-year mean gradient was 11.7 ± 5.6 mm Hg overall. Reintervention rates were low in both groups (isolated SAVR, 2.3% vs concomitant SAVR, 5.0%; P = .21), and most patients (isolated SAVR, 87.9%; concomitant SAVR, 86.1%) were alive with no evidence of bioprosthetic valve failure at 5 years.

Conclusions: SAVR in low-risk patients in the PARTNER 3 trial demonstrated excellent 5-year outcomes. Five-year mortality was similar in patients undergoing isolated SAVR vs concomitant SAVR. This result was comparable to recently published national SAVR outcomes, thus demonstrating the generalizability of these findings.

PubMed Disclaimer

Conflict of interest statement

Disclosures Vinod H. Thourani reports a relationship with Abbott Vascular that includes: consulting or advisory; with AtriCure that includes: consulting or advisory; with Artivion that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; with Edwards Lifesciences that includes: consulting or advisory; with Medtronic that includes: consulting or advisory; with JenaValve Technology that includes: consulting or advisory; with Highlife that includes: consulting or advisory; with Croivalve that includes: consulting or advisory; and with Dasi Simulations that includes: equity or stocks. Martin B. Leon reports a relationship with W.L. Gore & Associates Medical Products Division that includes: consulting or advisory; with Meril Life Sciences that includes: consulting or advisory; with Medtronic that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; and with Abbott that includes: consulting or advisory. Raj Makkar reports a relationship with Cordis that includes: consulting or advisory; and with Medtronic that includes: consulting or advisory. Wilson Y. Szeto reports a relationship with Terumo Interventional Systems that includes: consulting or advisory; with MicroInterventional Devices that includes: consulting or advisory; and with Cardiac Dimensions that includes: consulting or advisory. Susheel K. Kodali reports a relationship with Philips that includes: consulting or advisory; with Admedus that includes: consulting or advisory and equity or stocks; with TriCares that includes: consulting or advisory; with Dura Biotech that includes: consulting or advisory and equity or stocks; with Thubrikar Aortic Valve that includes: equity or stocks; with MicroInterventional Devices that includes: equity or stocks; with Supira that includes: equity or stocks; with TriFlo that includes: equity or stocks; with Adona that includes: equity or stocks; and with Tioga that includes: equity or stocks. Rebecca T. Hahn reports a relationship with Abbott that includes: speaking and lecture fees; with Baylis Medical Company that includes: speaking and lecture fees; with Edwards Lifesciences that includes: speaking and lecture fees; with Medtronic that includes: speaking and lecture fees; with Philips that includes: speaking and lecture fees; and with Siemens that includes: speaking and lecture fees. S. Chris Malaisrie reports a relationship with Medtronic that includes: funding grants; with Edwards Lifesciences that includes: consulting or advisory; with Terumo Interventional Systems that includes: consulting or advisory; and with Artivion that includes: consulting or advisory. Howard C. Herrmann reports a relationship with Abbott that includes: consulting or advisory; with Edwards Lifesciences that includes: consulting or advisory; with Medtronic that includes: consulting or advisory; with Johnson & Johnson that includes: consulting or advisory; with Prolifagen that includes: consulting or advisory; and with MicroInterventional Devices that includes: equity or stocks. Vasilis Babaliaros reports a relationship with Edwards Lifesciences that includes: consulting or advisory; and with Transmural Systems that includes: equity or stocks. Philippe Genereux reports a relationship with Abbott that includes: consulting or advisory; with AbioMed that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; with Caranx Medical that includes: consulting or advisory; with Cardiovascular Systems that includes: consulting or advisory; with Edwards Lifesciences that includes: consulting or advisory; with Egnite that includes: consulting or advisory; with GE Healthcare that includes: consulting or advisory; with iRhythm Technologies that includes: consulting or advisory; with Medtronic that includes: consulting or advisory; with Shockwave Medical that includes: consulting or advisory; with Siemens that includes: consulting or advisory; with Teleflex that includes: consulting or advisory; with 4C Medical Technologies that includes: consulting or advisory; with Pi-Cardia that includes: equity or stocks; with Puzzle Medical that includes: equity or stocks; with Soundbite Medical that includes: equity or stocks; and with Saranas that includes: equity or stocks. David J. Cohen reports a relationship with Abbott that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; and with Edwards Lifesciences that includes: consulting or advisory; and with Elixir Medical that includes: consulting or advisory. Molly Szerlip reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with Boston Scientific that includes: consulting or advisory; and with Abbott that includes: consulting or advisory. Julien Ternacle reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with Abbott that includes: consulting or advisory; with GE Medical that includes: consulting or advisory; and with Philips that includes: consulting or advisory. Jonathon Leipsic reports a relationship with HeartFlow Inc that includes: consulting or advisory; and with Circle CVI that includes: consulting or advisory. Philipp Blanke reports a relationship with Edwards Lifesciences that includes: consulting or advisory; and with Laralab that includes: consulting or advisory. John G. Webb reports a relationship with Edwards Lifesciences that includes: consulting or advisory.

Publication types

LinkOut - more resources